Prescribing guide
Vyndamax (tafamidis)Dosing, the Vyndaqel conversion, specialty pharmacy routing and prior authorization criteriaFor prescribers and their offices treating ATTR amyloidosis with cardiomyopathy: what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
No REMS; prior authorization where the plan requires it, a specialty pharmacy in the plan's network, and shipment to the patient's home once approved.
Example PA threshold
Cigna example: age 18 or older, PYP scintigraphy, biopsy with TTR typing or a TTR pathogenic variant, imaging showing cardiac involvement, heart failure without NYHA class IV, cardiologist or amyloidosis specialist, no concurrent acoramidis or TTR silencer.
Monitoring
No required monitoring in the label; total thyroxine may fall without a TSH change, and BCRP substrate toxicity is watched when co-prescribed.
Support line
VynAssist, 1-888-863-1177, Access Care Manager, copay as little as $0 a month (maximum $10,000 to $60,000 a year) for commercial plans, though the posted terms still say the offer expires 12/31/25, the Pfizer Patient Assistance Program through VyndaLink (1-888-222-8475) for uninsured or government-insured patients.
Give your patient their plan
A one-page handout for starting Vyndamax, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/vyndamaxBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Prescribe the right product | Vyndamax 61mg, one capsule once daily. Vyndaqel, NDA 211996, is listed as discontinued on Drugs@FDA. Both cartons carry an Attention Pharmacist line that the products are not substitutable on a per mg basis. | FDA label |
| Submit the prior authorization | Pfizer points offices to CoverMyMeds for PAs and renewals at no cost. Include the confirming test, the cardiac imaging and the NYHA class. | VynAssist HCP |
| Route to a specialty pharmacy | Pfizer lists 6 national specialty pharmacies and over 175 IDNs; an eligible IDN specialty pharmacy can also be used. | VynAssist HCP |
| Network pharmacies | CenterWell Specialty Pharmacy, CVS Specialty, Walgreens Specialty Pharmacy, Optum Specialty Pharmacy, Orsini Specialty Pharmacy and Accredo, per Pfizer's May 2025 list. Pfizer says choosing one aligned to the patient's insurer may reduce access barriers. | Specialty pharmacy list |
| Enroll the patient in VynAssist | Patients who opt in get an Access Care Manager, a single point of contact for the patient and care team; 1-888-863-1177, Monday to Friday, 8 AM to 7 PM ET. | VynAssist HCP |
| Medication reconciliation | Flag BCRP substrates such as methotrexate, rosuvastatin and imatinib. No contraindications. The Patient Information asks patients to disclose liver problems and all medicines and supplements. | FDA label |
| Pregnancy | No pregnancy test or contraception requirement. The label advises considering pregnancy planning and prevention, advises against breastfeeding, and asks that pregnancies be reported to 1-800-438-1985. | FDA label |
Prior authorization criteria and what to document
One public policy as the example: Cigna, March 1, 2026. Approval a year at a time. This policy took effect March 1, 2026 and cites the October 2023 prescribing information, which is the current label text. It still names Vyndaqel, which Drugs@FDA now lists as discontinued. Cigna notes that wild-type disease has no TTR variant, so a genetic test cannot be the confirming test for it. It is here as an example of what a plan asks for, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Age | 18 years or older | Date of birth on the request | Cigna policy |
| Diagnosis confirmation | One of a technetium pyrophosphate scan, a tissue biopsy with TTR typing by mass spectrometry, immunoelectron microscopy or immunohistochemistry, or genetic testing showing a TTR pathogenic variant; documentation required | Scan, pathology or genetic report; wild-type disease relies on the scan or biopsy | Cigna policy |
| Cardiac involvement | Diagnostic cardiac imaging demonstrating involvement, for example increased ventricular wall or septal thickness | Echo or cardiac MRI report | Cigna policy |
| Heart failure class | Heart failure present, but not NYHA class IV | The functional class in the note | Cigna policy |
| Prescriber | Prescribed by or in consultation with a cardiologist or a physician who specializes in amyloidosis | Specialty on the request, or the consult note | Cigna policy |
| No combination | Not covered with Amvuttra, Attruby, Onpattro, Tegsedi or Wainua, or with Vyndaqel and Vyndamax together | Current medication list | Cigna policy |
| Approval | 1 year | Calendar the renewal date | Cigna policy |
| Medicare plan year | Pfizer says a renewal or a new PA is needed for each new plan year, and a changed plan needs a new PA | The patient's new plan card, usually late December | VynAssist Medicare |
Vyndamax dosing and titration
| When | Label | Source |
|---|---|---|
| Day 1 onward | Vyndamax 61mg orally once daily, one capsule, swallowed whole, not crushed or cut. No titration. No dosage adjustment for patients 65 or older, and no clinically significant pharmacokinetic differences with renal or mild hepatic impairment. | FDA label |
| Alternative on the label | Vyndaqel 80mg, four 20mg tafamidis meglumine capsules once daily. Not substitutable with Vyndamax on a per mg basis. | FDA label |
| Food | No clinically significant effect of a high fat, high calorie meal on pharmacokinetics. | FDA label |
| Missed dose | Take as soon as remembered or skip and take the next dose at the regular time; do not double the dose. | FDA label |
| How supplied | Vyndamax: carton of 3 blister cards of 10, 30 capsules, NDC 0069-8730-30. Vyndaqel: carton of 120 capsules, NDC 0069-1975-40. Store at 20 to 25 degrees C (68 to 77 F). | FDA label |
| Overdose | Minimal experience; 2 trial patients took a single 160mg Vyndaqel dose without adverse events. | FDA label |
Monitoring the Vyndamax label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Baseline | No required test | The label has no boxed warning, contraindications or Warnings and Precautions section | FDA label |
| Any time | Thyroid function tests | Total thyroxine may decrease without a TSH change, attributed to displacement from TTR; no clinical hypothyroidism observed | FDA label |
| Any time | BCRP substrate toxicity | Rosuvastatin AUC up 96.75% and Cmax up 85.59% with Vyndamax 61mg; modify the substrate dose if appropriate | FDA label |
| Hepatic impairment | Moderate (Child-Pugh 7 to 9): exposure about 40% lower | The label says exposure relative to lower TTR levels still maintains stabilization; severe impairment effect unknown | FDA label |
| Efficacy | ATTR-ACT: 441 patients, 30 months, Vyndaqel 20mg or 80mg against placebo | Pooled Vyndaqel: all-cause mortality HR 0.70; CV hospitalization relative risk ratio 0.68; 6MWT and KCCQ-OS benefit first seen at month 6 | FDA label |
| Safety | ATTR-ACT adverse events | Frequency similar to placebo; discontinuation 7% on 80mg against 6% on placebo | FDA label |
| Pharmacokinetics | Half-life about 49 hours; peak within 4 hours | No clinically relevant QTc prolongation at about 2.2 times steady-state Cmax | FDA label |
Vyndamax drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| BCRP substrates | Tafamidis inhibits BCRP; may increase exposure to methotrexate, rosuvastatin, imatinib and similar substrates. Monitor for substrate-related toxicity and adjust the substrate dose if appropriate | FDA label |
| CYP3A4 substrates | No clinically significant change in midazolam pharmacokinetics after 14 days of Vyndaqel 20mg | FDA label |
| In vitro | Tafamidis induces CYP2B6 and CYP3A4 and inhibits intestinal UGT1A1; it does not inhibit the main CYP enzymes, P-gp, OCT2, MATE1, MATE2K, OATP1B1 or OATP1B3 | FDA label |
| Other TTR therapies | The label does not address combination use. The Cigna policy excludes concurrent Amvuttra, Attruby, Onpattro, Tegsedi or Wainua, citing no controlled trial data on additive efficacy | Cigna policy |
| Contraindications | None | FDA label |
Why a first fill stalls, and the fix
- Prior authorization pending or deniedThe Cigna policy below wants the diagnosis confirmed by a heart scan, biopsy or genetic test, heart imaging, and heart failure short of NYHA class IV. A VynAssist Access Care Manager can explain what the plan is asking for and coordinate with the office.
- You already take Attruby or a TTR silencerCigna does not cover tafamidis used alongside Amvuttra, Attruby, Onpattro, Tegsedi or Wainua. Which treatment to use is the cardiologist's decision, and the insurer decides what it pays for.
- The prescription or approval is for VyndaqelDrugs@FDA lists Vyndaqel as discontinued, and Pfizer says a switch to Vyndamax will likely need a new prescription and prior authorization. Cigna also will not cover both forms at once.
- The pharmacy is not in your plan's networkThe VyndaLink line, 1-888-222-8475, helps when you and your doctor do not know which specialty pharmacy is in network with your plan. It also helps when coverage was denied and more research is needed.
- A copay you cannot payCommercial insurance: the copay program, as little as $0 a month, with a maximum of $10,000 to $60,000 a year. Medicare, Medicaid, TRICARE, VA and other government plans are excluded by its terms. Pfizer's posted terms still say the offer expires December 31, 2025, so ask VyndaLink at 1-888-222-8475 whether it runs in 2026. The Pfizer Patient Assistance Program is for uninsured or government-insured patients who qualify.
- A new Medicare plan yearPfizer says a Medicare drug plan needs a renewal or new prior authorization for each new year. Its page suggests refilling before December 31st if a refill falls in late December.
VynAssist
- An Access Care Manager who explains your coverage and expected costs, and what to expect from the specialty pharmacy
- A Co-Pay Savings Program for commercial insurance, as little as $0 a month, with a $10,000 to $60,000 yearly maximum, not open to Medicare, Medicaid, TRICARE, VA or cash payers. Its full terms page still says the offer expires December 31, 2025
- The Pfizer Patient Assistance Program through VyndaLink (1-888-222-8475), for uninsured or government-insured patients with household income up to 300% of the federal poverty level
- For Medicare, help with plan changes and the Medicare Prescription Payment Plan, which Pfizer requires before its assistance program will consider a Part D patient
- Information on independent third-party financial support, which Pfizer says you must apply to and be denied by before its assistance program will consider you
Questions prescribers' offices ask about Vyndamax
What is the Vyndamax dose, and how does it relate to Vyndaqel?
The DailyMed label version effective May 12, 2026 gives 61mg once daily, one capsule, or Vyndaqel 80mg, four 20mg capsules once daily. The 2 are not substitutable on a per mg basis; the 61mg capsule matched four 20mg capsules in steady-state Cmax and AUC. Drugs@FDA lists Vyndaqel as discontinued, and Pfizer says switching will likely need a new prescription and prior authorization.
Is any monitoring required on Vyndamax?
None is required by the DailyMed label version effective May 12, 2026, which has no boxed warning, no contraindications, and no Warnings and Precautions section, and the FDA REMS list does not include tafamidis. It notes lower total thyroxine without a TSH change, and no clinically relevant QTc prolongation at about 2.2 times steady-state Cmax.
Which drugs interact with Vyndamax?
BCRP substrates, per section 7.1 of the DailyMed label version effective May 12, 2026. Tafamidis inhibits BCRP and may raise exposure to methotrexate, rosuvastatin and imatinib; rosuvastatin AUC rose 96.75% with Vyndamax 61mg. Monitor for substrate toxicity and adjust the substrate dose if appropriate.
What does the label say about pregnancy and lactation?
The DailyMed label version effective May 12, 2026 says tafamidis may cause fetal harm based on animal studies, and to consider pregnancy planning and prevention in females of reproductive potential. Breastfeeding is not recommended. Pregnancies are reported to Pfizer at 1-800-438-1985.
What do insurers ask for to approve Vyndamax?
The Cigna policy on this page, effective March 1, 2026, asks for age 18 or older and confirmation by technetium pyrophosphate scintigraphy, biopsy with TTR typing, or a TTR pathogenic variant. It also wants imaging showing cardiac involvement, heart failure short of NYHA class IV and a cardiologist or amyloidosis specialist. It excludes concurrent Attruby or TTR silencers, and approves for 1 year.
Free email alert
Get an email when the Vyndamax label changes
One email the day the FDA revises the Vyndamax prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Vyndamax only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- VYNDAQEL- tafamidis meglumine capsule, liquid filled; VYNDAMAX- tafamidis capsule, liquid filled: prescribing information and Patient Information, DailyMed version 15 (text revised October 2023), Pfizer, via DailyMed, 2026-05-12.
- Drugs@FDA: FDA-Approved Drugs, NDA 211996 (VYNDAQEL, marketing status Discontinued), FDA, 2026-11-07.
- Approved Risk Evaluation and Mitigation Strategies (REMS), FDA, 2026-11-07.
- VynAssist | VYNDAMAX® (tafamidis) Patient Support, Pfizer, 2026-11-07.
- Financial Assistance | VynAssist | VYNDAMAX® (tafamidis) Patient Support, Pfizer, 2026-11-07.
- Copay Terms and Conditions | VynAssist | VYNDAMAX® (tafamidis) Patient Support, Pfizer, 2026-11-07.
- Medicare 2027 | VynAssist | VYNDAMAX® (tafamidis) Patient Support, Pfizer, 2026-11-07.
- Access Support | VynAssist | VYNDAMAX® (tafamidis) Patient Support, Pfizer, 2026-11-07.
- VynAssist | VYNDAMAX® (tafamidis) HCP Support, Pfizer, 2026-11-07.
- VyndaLink® Enrollment Form (PP-VDM-USA-2396), Pfizer, 2026-11-07.
- VYNDAMAX specialty pharmacy information (PP-VDM-USA-2216, May 2025), Pfizer, 2025-05-01.
- Financial Assistance | VYNDAMAX® (tafamidis) | Safety Info, Pfizer, 2026-11-07.
- Amyloidosis - Tafamidis Products, Drug Coverage Policy IP0149, Cigna, 2026-03-01.
- NDA 211996/S-002 and NDA 212161/S-002 supplement approval letter, THAOS registry text removed, FDA, 2023-10-17.
- NDA 211996/S-001 and NDA 212161/S-001 supplement approval letter, BCRP interaction labeling, FDA, 2021-06-01.
- NDA 211996 and NDA 212161 approval letter, FDA, 2019-05-03.
A reference drawn from the May 12, 2026 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 7, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.